A single lot of Eugia vancomycin injection is under nationwide recall after a glass particle was identified inside a vial.

Eugia US LLC, formerly Auro Medics Pharma LLC, announced the voluntary recall on November 6, 2026; FDA posted the announcement on November 9.

The affected product is Vancomycin Hydrochloride for Injection USP, 1.25 g per 30-mL single-dose vial. The recall reaches hospitals, healthcare facilities and users. [1]

How to Identify the Recalled Lot

Eugia shipped the lot to wholesalers nationwide from September 2 through September 15, 2026.

The finding concerns a glass particle identified inside a vial; FDA's announcement does not establish that every vial in the recalled lot contains glass. Nor does it implicate other vancomycin products. [1]

Why Glass Particles in an Injection Matter

The concern is unintended intravascular particulate exposure, not a change in vancomycin's antimicrobial properties.

The FDA-posted company risk statement warns that injected glass particles could obstruct blood vessels, impair blood flow and potentially contribute to pulmonary embolism, permanent organ injury or death.

Local vein irritation, phlebitis, inflammatory reactions and allergic responses are also possible.

Eugia highlights greater potential susceptibility among neonates, infants and patients with compromised organ function.

These are potential complications—not documented outcomes from this recall.

Eugia reported no related adverse events as of its November 6 announcement. [1]

What Hospitals and Pharmacies Should Do

Eugia instructs wholesalers, hospitals, pharmacies, institutions and clinicians holding the affected lot to discontinue use immediately and quarantine inventory.

Organizations that redistributed the lot should notify downstream recipients and affected locations. Hospitals should also inform their healthcare professionals.

The company is contacting customers by recall letter and arranging returns or replacements. [1]

For return arrangements, the FDA notice lists Qualanex at 1-800-505-9291 or recall@qualanex.com. Suspected adverse events or product-quality problems can be reported through FDA MedWatch.

MedicalToxic previously covered a separate injectable-particle event in FDA Posts Recall of 22 Argatroban Lots Over Particles. That recall involved different products and materials; it should not be combined with this single-lot vancomycin action.

What Is New—and What Remains Unknown?

The new development is a November 9 FDA-posted, lot-specific nationwide recall following the identification of a glass particle inside one vial.

The notice does not provide a contaminated-vial count, a patient-exposure denominator or evidence of particulate-related patient injuries.

Bottom line: Healthcare facilities should check both NDCs and lot 3VM26026A, quarantine affected stock and follow the manufacturer's return process.

The recall does not call for avoiding all vancomycin injections or changing vancomycin dosing.

References

1. U.S. Food and Drug Administration. (2026, November 9; company announcement November 6). Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter.